Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib-based combination therapy in previously treated soft tissue sarcoma
ChiCTR2400084978Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of vorolanib in soft tissue sarcoma (STS) (2 cohorts), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Objective response rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
vorolanib
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on ChiCTR2400084978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084978.